Leadership

Scientist and entrepreneur leading WuXi since its founding in 2000. Ph.D. in Organic Chemistry from Columbia University. Awards and honors include "2018 SAPA Distinguished Achievement Award", "2018 The 40 Most Influential People in Pharmaceutical Industry in Commemoration of the 40th Anniversary of Reform and Opening-up", "2016 CBA Brilliant Achievement Award", "2015 SCRIP Executive of the Year Award", "2015 The 25 Most Influential People in Biopharma", "2009 The 60 Most Influential People during 60 Years Pharmaceutical Development in China", "2008 Forbes 25 Notable Chinese-Americans", and "2007 Ernst & Young Entrepreneur of the Year China".

A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco.

With more than 20 years of experience in the pharmaceutical industry, Johnathan has over 14 years of clinical trial management experience in the United States, has participated in and led a number of early-phase projects, and managed Phase III studies, including the successful launch of leukemia and oncology indications for Gleevec and Zoledronate during his work at Novartis, USA. After returning to China in 2010, he worked at the Bayer Global R&D Center in clinical project management, and for Roche (China) as head of the region for Roche's global program. In 2014, he served as the Head of Project Management at IQVIA (Greater China), where he was instrumental in leading the departments significant growth in size, expertise, and project success. Johnathan received his MD from Capital Medical University in 1993. In 1997, he obtained his Masters in BMS and Biomolecular Science from NYU.

Dr. Shen was co-founder, President & CEO of Pharmapace, Inc., a consulting and CRO company to the biopharma industry, which was acquired by WuXi AppTec in 2019. He has a highly accomplished career in leading clinical organizations to support drug development programs. He has directly worked on approximately 30 investigational new drug projects and played leading roles in regulatory submissions that led to 7 drug approvals in both the US and European Union. Dr. Shen has served as senior statistical advisor to numerous biopharma companies as well as member of data/safety monitoring committees. He is a fellow of the American Statistical Association (ASA) and has served as past President of the San Diego Chapter of ASA.   

Dr. Wang has worked on designing, implementing, analyzing, and reporting all phases of clinical trials over 20 years across a wide spectrum of biopharmaceuticals and medical devices. He has extensive experience in regulatory submissions, interactions with regulatory authorities, product in-licensing, and commercial development. Dr. Wang’s current research interests include applying innovative statistical methodologies into clinical trial designs. He has been providing extensive consultation to clients on study designs and lectures both internally and externally. Prior to joining WuXi Clinical, he worked for PAREXEL as senior director and head of biostatistics, Asia-Pacific Region. Before that, he had senior roles with global pharmaceutical and medical device companies in the US including St. Jude Medical (now Abbott ) and Allergan. Dr. Wang received his PhD degree in Mathematics and completed his postdoctoral fellowship in Biostatistics and Epidemiology in the US.

Alfonso has been in the clinical development industry for over 37 years. Prior to joining WuXi Clinical, Alanís was the CEO and Chairman of the Board of Anaclim LLC, a CRO focused on the enrollment of ethnically-balanced populations into clinical trials. Prior to working at Anaclim, Alfonso was an Executive at Eli Lilly and Company where he served in different functions for 21 years, including 7 years as the Chief Medical Officer and Vice President of Global Clinical Research. Alfonso was born in Mexico City where he attended Medical School, graduating magna cum laude from the National Autonomous University of Mexico (UNAM). He obtained his Internal Medicine, Infectious Disease and Clinical Microbiology training at the Cleveland Clinic in Cleveland, Ohio. Alfonso has been the recipient of different academic and research awards and honors, and has authored several scientific publications and chapters in peer-reviewed medical journals and medical books.

Mr. Nelson leads the Clinical Operations and Business Development teams for North America and Europe. He directs operations initiatives and leads the US business development efforts with key customers. Mr. Nelson also serves as the Site Head of Austin, Texas. Steven has over 30 years of Clinical Operations experience working for both large and smaller corporations including Pfizer, Roche, Merck/Foxollow, Schering-Plough, and Innapharma. Steven Nelson has a MBA in Global Management/Marketing from New York University and a Bachelor’s of Science in Biology from Fairleigh Dickinson University in New Jersey.

David has over 25 years of experience in biostatistics, data management, and strategic management. David's clinical development experience covers drugs, biologics, and devices and has extensive experience in a wide range of therapeutic areas, including oncology, heart disease, central nervous system, immunology, and infectious diseases. David has successfully designed the proof-of-concept endpoints and research, and the project he was in charge of has been approved after it was submitted to the FDA. David is committed to establishing data management services in Asia and has been involved in the development of data management systems and processes for more than 25 years.